



## Complete Summary

---

### GUIDELINE TITLE

Chronic obstructive pulmonary disease (COPD).

### BIBLIOGRAPHIC SOURCE(S)

Finnish Medical Society Duodecim. Chronic obstructive pulmonary disease (COPD).  
In: EBM Guidelines. Evidence-Based Medicine [CD-ROM]. Helsinki, Finland:  
Duodecim Medical Publications Ltd.; 2004 Jun 28 [various]. [63 references]

## COMPLETE SUMMARY CONTENT

SCOPE  
METHODOLOGY - including Rating Scheme and Cost Analysis  
RECOMMENDATIONS  
EVIDENCE SUPPORTING THE RECOMMENDATIONS  
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS  
IMPLEMENTATION OF THE GUIDELINE  
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT  
CATEGORIES  
IDENTIFYING INFORMATION AND AVAILABILITY

## SCOPE

### DISEASE/CONDITION(S)

Chronic obstructive pulmonary disease (COPD)

### GUIDELINE CATEGORY

Diagnosis  
Management  
Treatment

### CLINICAL SPECIALTY

Family Practice  
Internal Medicine  
Pulmonary Medicine

### INTENDED USERS

Health Care Providers  
Physicians

## GUIDELINE OBJECTIVE(S)

Evidence-Based Medicine Guidelines collect, summarize, and update the core clinical knowledge essential in general practice. The guidelines also describe the scientific evidence underlying the given recommendations.

## TARGET POPULATION

- Adults with chronic obstructive pulmonary disease (COPD)
- Adults requiring evaluation for possible chronic obstructive pulmonary disease

## INTERVENTIONS AND PRACTICES CONSIDERED

### Diagnosis

1. Physical examination and assessment of signs and symptoms
2. Spirometry in combination with active promotion of smoking cessation
3. Assessment of forced expiratory volume in one second/forced vital capacity (FEV<sub>1</sub>/FVC)
4. Test with a bronchodilating drug and subsequent assessment of response (as measured by spirometry and bronchodilator dose or peak expiratory flow [PEF] follow-up)
5. Evaluation of the effectiveness of anti-inflammatory treatment with a trial of steroids (oral prednisolone or inhaled steroid)
6. Assessment of diffusion capacity
7. Blood gas analysis
8. Chest radiograph

### Treatment

1. Cessation of smoking
2. Drug therapy
  - Bronchodilating medication (Inhaled anticholinergic drug: short acting [ipratropium or oxitropium bromide] or long acting [tiotropium]; inhaled beta-sympathomimetic [salbutamol, terbutaline, fenoterol, formoterol, salmeterol] possibly in combination with anticholinergic drug; oral, long-acting theophylline)
  - Anti-inflammatory medication (inhaled steroids for patients who objectively benefit from a trial of steroids)
3. Nonpharmacologic measures to promote mucous excretion (expiration resistance [positive expiratory pressure [PEP] mouthpiece] or blowing air through a straw into a bottle filled with water, combined with effective coughing)
4. Treatment of acute exacerbation with oxygen by nasal catheter or by venturi mask, noninvasive ventilation, an inhaled sympathomimetic (salbutamol or terbutaline) by a dosing device or a spray, possibly in combination with an inhaled ipratropium bromide, theophylline infusion if response to other treatments is poor, methyl prednisolone or oral corticosteroids (prednisolone)
5. Treatment of acute infection with antimicrobials (amoxicillin, doxycycline, sulfa-trimethoprim)
6. Exercise
7. Vaccinations (influenza, pneumococcal, haemophilus influenzae)

## 8. Oxygen therapy at home

Note: Guideline developers considered, but did not recommend the following interventions: combined corticosteroid and long acting beta-agonist, nutritional support, cardioselective beta-blockers for short-term reduction in airway function, vibration for clearing bronchial secretions, and nocturnal positive pressure ventilation.

### MAJOR OUTCOMES CONSIDERED

- Symptom relief
- Exercise capacity
- Lung function (as measured by spirometry)
- Morbidity and mortality
- Quality of life
- Frequency and severity of exacerbations

## METHODOLOGY

### METHODS USED TO COLLECT/SELECT EVIDENCE

Hand-searches of Published Literature (Primary Sources)  
Hand-searches of Published Literature (Secondary Sources)  
Searches of Electronic Databases

### DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

The evidence reviewed was collected from the Cochrane database of systematic reviews and the Database of Abstracts of Reviews of Effectiveness (DARE). In addition, the Cochrane Library and medical journals were searched specifically for original publications.

### NUMBER OF SOURCE DOCUMENTS

Not stated

### METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Weighting According to a Rating Scheme (Scheme Given)

### RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Levels of Evidence

- A. Strong research-based evidence. Multiple relevant, high-quality scientific studies with homogeneous results.
- B. Moderate research-based evidence. At least one relevant, high-quality study or multiple adequate studies.
- C. Limited research-based evidence. At least one adequate scientific study.
- D. No research-based evidence. Expert panel evaluation of other information.

## METHODS USED TO ANALYZE THE EVIDENCE

Review of Published Meta-Analyses  
Systematic Review

## DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

## METHODS USED TO FORMULATE THE RECOMMENDATIONS

Not stated

## RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

## COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

## METHOD OF GUIDELINE VALIDATION

Peer Review

## DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Not stated

# RECOMMENDATIONS

## MAJOR RECOMMENDATIONS

The levels of evidence [A-D] supporting the recommendations are defined at the end of the "Major Recommendations" field.

### Basic Rules

- Consider the diagnosis of chronic obstructive pulmonary disease (COPD) in any smoker who has the following: symptoms of cough, sputum production, or dyspnoea.
- Make early diagnosis by spirometry and promote smoking cessation.
- In mild COPD, forced expiratory volume in one second/forced vital capacity (FEV<sub>1</sub>/FVC) is below 0.7 and FEV% >80% predicted (Global Initiative for Chronic Obstructive Lung Disease [GOLD] criteria).
- A trial of steroids must be performed if starting long-term steroid treatment is considered.
- Most important differential diagnostic problem is asthma. Also many asthmatics smoke.

## Definitions

- Chronic bronchitis: sputum at least for 3 months in 2 consecutive years.
- Pulmonary emphysema (is a pathologic anatomic diagnosis): terminal air spaces widen and alveolar walls rupture.
- Chronic obstructive pulmonary disease (COPD): the patient has chronic, mainly progressive airway obstruction, with no significant response to treatment.

## Aetiology

- Most COPD patients (>95%) are smokers. Half of those who smoke have symptoms of chronic bronchitis. In 15 to 20% of smokers, a slowly aggravating airway obstruction is detected.
- Deficiency of alpha-1-antitrypsin is a rare cause of emphysema in young patients.

## Symptoms

- Cough and sputum excretion are common symptoms of chronic bronchitis.
- Patients with progressive disease suffer from slowly increasing dyspnoea during exercise.
- The symptoms are aggravated by respiratory infection.

## Signs

- Most patients seek for a doctor late, when the disease is already moderate to severe. In mild disease auscultation may be normal and no auscultatory signs for obstruction can be detected.
- Absence of the following signs of severe COPD does not exclude the existence of mild COPD.
- Because of airway obstruction, wheezing rattles may be heard at the end of forced expiration.
- The patient with advanced emphysema has a barrel-chested appearance, in auscultation silent respiratory sounds are heard and in percussion the sound is hypersonic.
- Cyanosis is associated with hypoxaemia.

## Complications

- Acute
  - Repeated and prolonged lower respiratory infections
  - Acute respiratory failure
  - Pneumothorax (disruption of emphysematic bullae)
- Chronic
  - Cardiopulmonary disease

## Diagnosis

- Early diagnosis by spirometry in combination with active promotion of smoking cessation is essential.

- Test with a bronchodilating drug
  - The objective response to a bronchodilator (increase >15%) is measured with spirometry and bronchodilator dose (e.g. inhaled salbutamol 400 micrograms twice daily), or peak expiratory flow (PEF) rate follow-up for two weeks.
- Evaluate the effectiveness of anti-inflammatory treatment with a trial of steroids.
  - Oral prednisolone, initially 30 to 40 mg/day (if necessary, give protection against ulcers, e.g. a proton pump inhibitor [PPI]), or inhaled steroid (e.g., budesonide 800 micrograms twice daily). In oral administration the trial duration is 2 weeks, with an inhaled steroid 6 weeks.
  - If there is an objective response (PEF or FEV<sub>1</sub> increase >15% and at least 200 mL), continue with inhalation steroid (the patient may also have asthma).
- Diffusion capacity
  - Decreased in COPD, normal in asthma.
- Blood gas analysis
  - In late stages of COPD arterial blood oxygen partial pressure (pO<sub>2</sub>) decreases and carbon dioxide partial pressure (pCO<sub>2</sub>) may increase
- Chest radiograph is of limited value in COPD diagnosis

## Treatment

### Cessation of Smoking

- The most essential factor regarding the prognosis
- Does not normalize lung function, but the progressive deterioration of FEV<sub>1</sub> slows down and proceeds at the same pace as in nonsmokers.
- According to present knowledge, there is no drug therapy available that could delay the deterioration of lung function if the patient continues smoking. Drugs act only by relieving subjective symptoms and in the treatment of acute exacerbations.

### Basic Rules of Drug Therapy

- Mild disease
  - Asymptomatic patients
    - No drug therapy
  - Patients with occasional symptoms (generally FEV<sub>1</sub> >50% predicted)
    - Anticholinergics or short-acting beta-2-agonists according to clinical response
    - Trial of steroids if asthma is suspected
- Continuous symptoms (generally FEV<sub>1</sub> <50% predicted)
  - Anticholinergics or short-acting beta-2-agonists (combined) according to clinical response or
  - Long acting anticholinergics or beta-2-agonists, or their combination
  - In selected cases inhaled glucocorticoid if frequent exacerbations
  - Trial of theophylline (Ram et al., "Oral theophylline," 2004)
  - Surgery (bullectomy, lung transplantation, lung volume reduction) can be recommended only to a small subset of the patients after careful evaluation

## Bronchodilating Medication

- Inhaled short acting (ipratropium or oxitropium bromide) or long acting (tiotropium) anticholinergic drug [C].
  - First line treatment
  - The dose must be high enough; administration 4 to 6 times daily with the short acting drug, once a day with the long acting tiotropium.
- Inhaled beta-sympathomimetic (salbutamol, terbutaline, fenoterol) [A]
  - May be combined with an anticholinergic drug
  - Long-acting beta-sympathomimetics (formoterol, salmeterol) may improve quality of life and reduce symptoms [C].
- Oral, long-acting theophylline (Ram et al., "Oral theophylline," 2004) [[A]
  - Adverse effects (central nervous system, gastrointestinal symptoms) are common (follow-up of serum concentrations is necessary).
  - Arrhythmias and convulsions are signs of toxicity.
  - Keep in mind various interactions with other drugs (e.g. antibiotics).

## Anti-inflammatory Medication

Inhaled steroids are only prescribed for patients who objectively benefit from a trial of steroids. The benefit in terms of lung function is very limited. Selected patients with frequent exacerbations may benefit from inhaled corticosteroid (van Grunsven et al., 1999; DARE-990281, 2001) [B].

## Treatment of Mucous Excretion

- If production of mucus is a problem, the patient may empty the lungs [D] at home
  - By performing forced expiration with the upper body tilted downwards (on the edge of the bed)
  - By using expiration resistance (positive expiratory pressure [PEP] mouthpiece) or blowing air through a straw into a bottle filled with water, combined with effective coughing
- Mucolytic agents should be used only temporarily [B].

## Treatment of Acute Exacerbation

- Oxygen by nasal catheter or by venturi mask. Caution should be exercised when dosing (if the result of an arterial blood gas analysis is not available, the concentration of mask oxygen should not exceed 28%, or nasal catheter flow should not exceed 2 L/min in patients above the age of 50 years).
- Noninvasive ventilation has improved the recovery in severe acute exacerbation of COPD (Ram et al., "Non-invasive," 2004) [A]
- An inhaled sympathomimetic (salbutamol 2.5–5 mg or terbutaline 5–10 mg) by a dosing device or a spray. Inhaled ipratropium bromide 0.5 mg can be added to it.
- There is no evidence of a significant effect of theophylline infusion [C] and its usage is not recommended. It may sometimes be used at a dose of 0.5 mg/kg/h if response to other treatments is poor. Serum theophylline concentration should be monitored if possible.

- Methyl prednisolone 0.5 mg/kg every 6 hours is probably beneficial. Also oral corticosteroids (prednisolone 30–40 mg/day) are used empirically for 7 to 14 days.

### Acute Infection

- Antimicrobial treatment in exacerbation of COPD is controversial (Saint et al., 1995; DARE-950358, 1999; Staykova et al., 2004) [B]. Factors that indicate starting antimicrobial treatment include:
  - Increased dyspnoea
  - Increased sputum
  - Purulent sputum
- If the patient exhibits two of the three symptoms listed above, an antimicrobial drug is usually indicated (Saint et al., 1995; DARE-950358, 1999; Staykova et al., 2004) [B].
- Alternatives in antimicrobial treatment:
  - Amoxicillin 500 mg three times daily for 10 days
  - Doxycycline 150 mg once daily for 10 days
  - Sulfa-trimethoprim, dose of trimethoprim 160 mg twice daily for 10 days.
- Antibiotics do not belong to the basic maintenance therapy of COPD.

### Improvement of Exercise Capacity

Long-lasting, regular, and moderate exercise (Lacasse et al., 1996; DARE-968413, 1999; Cambach et al., 1999; DARE-990269, 2000) [A]

### Vaccinations

- Influenza vaccination should be given yearly to all patients with clearly decreased ventilatory function [C].
- Pneumococcal vaccination is recommended.
- Haemophilus influenzae vaccination may also be beneficial [B].

### Oxygen Therapy at Home

#### Basics

- Oxygen therapy at home can be used to prevent elevation of pulmonary arterial pressure in advanced COPD and to extend the life of the patient.
- The effect of oxygen therapy on symptoms (e.g., shortness of breath) is quite limited.
- Oxygen therapy at home is meant only for patients with chronic hypoxaemia (i.e., arterial desaturation).
- Treatment decisions should be made after critical consideration.
- When initiating oxygen therapy at home, appropriate monitoring of treatment must be ensured. Treatment decisions and implementation of treatment should be the responsibility of the local pulmonary clinic.

#### Initiation Criteria for Oxygen Therapy



- Chronic, advanced pulmonary disease ( $FEV_1 < 1.5$  L)
- The partial pressure of oxygen in arterial blood, measured with the patient in stable phase of the disease breathing room air is  $< 7.3$  kPa in two samples taken with an interval of at least three weeks.
- Partial pressure of oxygen can also be 7.3 to 8.0 kPa if one of the following criteria is involved:
  - Signs of increased pulmonary arterial pressure (e.g., oedema)
  - Secondary polycythaemia (haematocrit  $> 55$ )
  - Significant nocturnal hypoxaemia established by oximetry and reversible by oxygen therapy and not caused by concomitant sleep apnoea syndrome
  - Significant neuropsychological symptoms reversible by oxygen therapy
- Oxygen therapy gives the desired response ( $PaO_2 > 8.0$  kPa) without unfavourable increase in the partial pressure of carbon dioxide in arterial blood.
- The patient does not smoke and is cooperative enough.

### Implementation of Treatment

- Oxygen therapy at home is currently implemented in most cases using an electric oxygen concentrator. The oxygen concentrator eliminates nitrogen from room air and provides the patient with over 90%-proof oxygen. Compressed tanks can still be used in places with no electricity.
- Portable liquid oxygen is suitable for a small group of patients. Primarily these are patients who are still working or who for some other reason have special needs for mobility.
- All oxygen therapy necessitates good cooperation by the patient and willingness for long-term cooperation with the treating unit.
- Home calls made by a rehabilitation instructor are an essential part of the monitoring of patients receiving oxygen therapy at home.

### Related Evidence

- Anti-cholinergic bronchodilators appear to have similar efficacy as beta-2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease (McCrory & Brown, 2004) [B].
- Combined corticosteroid and long acting beta-agonist (budesonide/formoterol or fluticasone/salmeterol) in one inhaler are modestly effective in reducing exacerbations and improving quality of life when compared to placebo, but there is little evidence of enhanced effectiveness compared to either of the components alone (Nannini, Lasserson, & Poole, 2003) [A].
- There is little evidence on the effectiveness of ambulatory domiciliary oxygen therapy on exercise capacity in patients with COPD [C].
- Noninvasive ventilation reduces mortality and need for intubation in severe exacerbations of COPD (Keenan & Brake, 1998; DARE-981397, 2000) [A].
- In patients with stable COPD, pressurized metered-dose inhalers (pMDIs) produce similar outcomes to dry powder devices for delivering beta-2 agonist [C].
- Nutritional support has no significant effect on anthropometric measures, lung function, or exercise capacity in patients with stable COPD [B].
- Cardioselective beta-blockers do not produce significant short-term reduction in airway function when given to patients with COPD [B].

- There is no clear evidence supporting vibration for clearing bronchial secretions (Thomas et al., 1995; DARE-965123, 1999) [D].
- Stapling is more effective than laser resection for lung volume reduction in diffuse emphysema, but there is no evidence from randomised trials comparing surgery with optimal conservative treatment [B].
- Nocturnal positive pressure ventilation does not appear to improve the condition of patients with COPD (Wijkstra et al., 2004.) [B].
- Hospital at home with support from specialized nurses is a safe alternative for about one in four selected patients with acute exacerbation of COPD (Ram et al., 2003) [A].

#### Definitions:

#### Levels of Evidence

- Strong research-based evidence. Multiple relevant, high-quality scientific studies with homogeneous results.
- Moderate research-based evidence. At least one relevant, high-quality study or multiple adequate studies.
- Limited research-based evidence. At least one adequate scientific study.
- No research-based evidence. Expert panel evaluation of other information.

#### CLINICAL ALGORITHM(S)

None provided

### EVIDENCE SUPPORTING THE RECOMMENDATIONS

#### REFERENCES SUPPORTING THE RECOMMENDATIONS

[References open in a new window](#)

#### TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

Concise summaries of scientific evidence attached to the individual guidelines are the unique feature of the Evidence-Based Medicine Guidelines. The evidence summaries allow the clinician to judge how well-founded the treatment recommendations are. The type of supporting evidence is identified and graded for select recommendations (see the "Major Recommendations" field).

### BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

#### POTENTIAL BENEFITS

Appropriate management and treatment of chronic obstructive pulmonary disease (COPD) may help relieve patient symptoms, improve exercise capacity, improve lung function, reduce morbidity and mortality, improve quality of life, and reduce frequency and severity of exacerbations.

#### POTENTIAL HARMS

## Adverse Effects of Medications

- Common adverse effects of oral, long-acting theophylline include central nervous system and gastrointestinal symptoms. Arrhythmias and convulsions are signs of toxicity.
- Adverse drug reactions of ipratropium bromide included dry mouth and tremor.

## IMPLEMENTATION OF THE GUIDELINE

### DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

## INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

### IOM CARE NEED

Getting Better  
Living with Illness

### IOM DOMAIN

Effectiveness  
Patient-centeredness

## IDENTIFYING INFORMATION AND AVAILABILITY

### BIBLIOGRAPHIC SOURCE(S)

Finnish Medical Society Duodecim. Chronic obstructive pulmonary disease (COPD). In: EBM Guidelines. Evidence-Based Medicine [CD-ROM]. Helsinki, Finland: Duodecim Medical Publications Ltd.; 2004 Jun 28 [various]. [63 references]

### ADAPTATION

Not applicable: The guideline was not adapted from another source.

### DATE RELEASED

2002 Apr 27 (revised 2004 Jun 28)

### GUIDELINE DEVELOPER(S)

Finnish Medical Society Duodecim - Professional Association

### SOURCE(S) OF FUNDING

Finnish Medical Society Duodecim

#### GUIDELINE COMMITTEE

Editorial Team of EBM Guidelines

#### COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Primary Author: Vuokko Kinnula

#### FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

#### GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Finnish Medical Society Duodecim. Chronic obstructive pulmonary disease (COPD). Helsinki, Finland: Duodecim Medical Publications Ltd.; 2002 Apr 27. Various p.

#### GUIDELINE AVAILABILITY

This guideline is included in a CD-ROM titled "EBM Guidelines. Evidence-Based Medicine" available from Duodecim Medical Publications, Ltd, PO Box 713, 00101 Helsinki, Finland; e-mail: [info@ebm-guidelines.com](mailto:info@ebm-guidelines.com); Web site: [www.ebm-guidelines.com](http://www.ebm-guidelines.com).

#### AVAILABILITY OF COMPANION DOCUMENTS

None available

#### PATIENT RESOURCES

None available

#### NGC STATUS

This summary was completed by ECRI on December 17, 2002. The information was verified by the guideline developer as of February 7, 2003. This NGC summary was updated by ECRI on October 1, 2004.

#### COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

© 1998-2005 National Guideline Clearinghouse

Date Modified: 1/24/2005

The logo for FIRSTGOV, with "FIRST" in blue and "GOV" in red, and a small red star above the "I".

